Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cartesian Therapeutics (RNAC) Return on Invested Capital (2022)

Historic Return on Invested Capital for Cartesian Therapeutics (RNAC) over the last 2 years, with Q4 2022 value amounting to 0.04%.

  • Cartesian Therapeutics' Return on Invested Capital fell 40900.0% to 0.04% in Q4 2022 from the same period last year, while for Dec 2022 it was 0.04%, marking a year-over-year decrease of 40900.0%. This contributed to the annual value of 0.21% for FY2024, which is 3000.0% down from last year.
  • As of Q4 2022, Cartesian Therapeutics' Return on Invested Capital stood at 0.04%, which was down 40900.0% from 0.13% recorded in Q3 2022.
  • Cartesian Therapeutics' Return on Invested Capital's 5-year high stood at 4.13% during Q4 2021, with a 5-year trough of 0.04% in Q4 2022.